Cor­rect­ed: Mer­ck KGaA bags an­oth­er pro­tein de­grad­er deal for $16M up­front, this time with C4

In the lat­est de­vel­op­ment in the “high­ly dy­nam­ic” pro­tein de­grad­er space, Mer­ck KGaA has inked a dis­cov­ery agree­ment with C4 Ther­a­peu­tics for two drugs against …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER